Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity.
Identifieur interne : 000194 ( Main/Exploration ); précédent : 000193; suivant : 000195Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity.
Auteurs : Andrew G. Diamos [États-Unis] ; Mary D. Pardhe [États-Unis] ; Haiyan Sun [États-Unis] ; Joseph G L. Hunter [États-Unis] ; Tsafrir Mor [États-Unis] ; Lydia Meador [États-Unis] ; Jacquelyn Kilbourne [États-Unis] ; Qiang Chen [États-Unis] ; Hugh S. Mason [États-Unis]Source :
- Vaccine [ 1873-2518 ] ; 2020.
Abstract
Zika virus (ZIKV) reemergence poses a significant health threat especially due to its risks to fetal development, necessitating safe and effective vaccines that can protect pregnant women. Zika envelope domain III (ZE3) has been identified as a safe and effective vaccine candidate, however it is poorly immunogenic. We previously showed that plant-made recombinant immune complex (RIC) vaccines are a robust platform to improve the immunogenicity of weak antigens. In this study, we altered the antigen fusion site on the RIC platform to accommodate N-terminal fusion to the IgG heavy chain (N-RIC), and thus a wider range of antigens, with a resulting 40% improvement in RIC expression over the normal C-terminal fusion (C-RIC). Both types of RICs containing ZE3 were efficiently assembled in plants and purified to >95% homogeneity with a simple one-step purification. Both ZE3 RICs strongly bound complement receptor C1q and elicited strong ZE3-specific antibody titers that correlated with ZIKV neutralization. When either N-RIC or C-RIC was codelivered with plant-produced hepatitis B core (HBc) virus-like particles (VLP) displaying ZE3, the combination elicited 5-fold greater antibody titers (>1,000,000) and more strongly neutralized ZIKV than either RICs or VLPs alone, after only two doses without adjuvant. These findings demonstrate that antigens that require a free N-terminus for optimal antigen display can now be used with the RIC system, and that plant-made RICs and VLPs are highly effective vaccines targeting ZE3. Thus, the RIC platform can be more generally applied to a wider variety of antigens.
DOI: 10.1016/j.vaccine.2020.02.089
PubMed: 32173095
PubMed Central: PMC7102565
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity.</title><author><name sortKey="Diamos, Andrew G" sort="Diamos, Andrew G" uniqKey="Diamos A" first="Andrew G" last="Diamos">Andrew G. Diamos</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Pardhe, Mary D" sort="Pardhe, Mary D" uniqKey="Pardhe M" first="Mary D" last="Pardhe">Mary D. Pardhe</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Sun, Haiyan" sort="Sun, Haiyan" uniqKey="Sun H" first="Haiyan" last="Sun">Haiyan Sun</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Hunter, Joseph G L" sort="Hunter, Joseph G L" uniqKey="Hunter J" first="Joseph G L" last="Hunter">Joseph G L. Hunter</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Mor, Tsafrir" sort="Mor, Tsafrir" uniqKey="Mor T" first="Tsafrir" last="Mor">Tsafrir Mor</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Meador, Lydia" sort="Meador, Lydia" uniqKey="Meador L" first="Lydia" last="Meador">Lydia Meador</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Kilbourne, Jacquelyn" sort="Kilbourne, Jacquelyn" uniqKey="Kilbourne J" first="Jacquelyn" last="Kilbourne">Jacquelyn Kilbourne</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Chen, Qiang" sort="Chen, Qiang" uniqKey="Chen Q" first="Qiang" last="Chen">Qiang Chen</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Mason, Hugh S" sort="Mason, Hugh S" uniqKey="Mason H" first="Hugh S" last="Mason">Hugh S. Mason</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States. Electronic address: hugh.mason@asu.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32173095</idno><idno type="pmid">32173095</idno><idno type="doi">10.1016/j.vaccine.2020.02.089</idno><idno type="pmc">PMC7102565</idno><idno type="wicri:Area/Main/Corpus">000191</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000191</idno><idno type="wicri:Area/Main/Curation">000191</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000191</idno><idno type="wicri:Area/Main/Exploration">000191</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity.</title><author><name sortKey="Diamos, Andrew G" sort="Diamos, Andrew G" uniqKey="Diamos A" first="Andrew G" last="Diamos">Andrew G. Diamos</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Pardhe, Mary D" sort="Pardhe, Mary D" uniqKey="Pardhe M" first="Mary D" last="Pardhe">Mary D. Pardhe</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Sun, Haiyan" sort="Sun, Haiyan" uniqKey="Sun H" first="Haiyan" last="Sun">Haiyan Sun</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Hunter, Joseph G L" sort="Hunter, Joseph G L" uniqKey="Hunter J" first="Joseph G L" last="Hunter">Joseph G L. Hunter</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Mor, Tsafrir" sort="Mor, Tsafrir" uniqKey="Mor T" first="Tsafrir" last="Mor">Tsafrir Mor</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Meador, Lydia" sort="Meador, Lydia" uniqKey="Meador L" first="Lydia" last="Meador">Lydia Meador</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Kilbourne, Jacquelyn" sort="Kilbourne, Jacquelyn" uniqKey="Kilbourne J" first="Jacquelyn" last="Kilbourne">Jacquelyn Kilbourne</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Chen, Qiang" sort="Chen, Qiang" uniqKey="Chen Q" first="Qiang" last="Chen">Qiang Chen</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Mason, Hugh S" sort="Mason, Hugh S" uniqKey="Mason H" first="Hugh S" last="Mason">Hugh S. Mason</name><affiliation wicri:level="2"><nlm:affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States. Electronic address: hugh.mason@asu.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Zika virus (ZIKV) reemergence poses a significant health threat especially due to its risks to fetal development, necessitating safe and effective vaccines that can protect pregnant women. Zika envelope domain III (ZE3) has been identified as a safe and effective vaccine candidate, however it is poorly immunogenic. We previously showed that plant-made recombinant immune complex (RIC) vaccines are a robust platform to improve the immunogenicity of weak antigens. In this study, we altered the antigen fusion site on the RIC platform to accommodate N-terminal fusion to the IgG heavy chain (N-RIC), and thus a wider range of antigens, with a resulting 40% improvement in RIC expression over the normal C-terminal fusion (C-RIC). Both types of RICs containing ZE3 were efficiently assembled in plants and purified to >95% homogeneity with a simple one-step purification. Both ZE3 RICs strongly bound complement receptor C1q and elicited strong ZE3-specific antibody titers that correlated with ZIKV neutralization. When either N-RIC or C-RIC was codelivered with plant-produced hepatitis B core (HBc) virus-like particles (VLP) displaying ZE3, the combination elicited 5-fold greater antibody titers (>1,000,000) and more strongly neutralized ZIKV than either RICs or VLPs alone, after only two doses without adjuvant. These findings demonstrate that antigens that require a free N-terminus for optimal antigen display can now be used with the RIC system, and that plant-made RICs and VLPs are highly effective vaccines targeting ZE3. Thus, the RIC platform can be more generally applied to a wider variety of antigens.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">32173095</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>18</Issue><PubDate><Year>2020</Year><Month>04</Month><Day>16</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity.</ArticleTitle><Pagination><MedlinePgn>3455-3463</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(20)30337-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2020.02.089</ELocationID><Abstract><AbstractText>Zika virus (ZIKV) reemergence poses a significant health threat especially due to its risks to fetal development, necessitating safe and effective vaccines that can protect pregnant women. Zika envelope domain III (ZE3) has been identified as a safe and effective vaccine candidate, however it is poorly immunogenic. We previously showed that plant-made recombinant immune complex (RIC) vaccines are a robust platform to improve the immunogenicity of weak antigens. In this study, we altered the antigen fusion site on the RIC platform to accommodate N-terminal fusion to the IgG heavy chain (N-RIC), and thus a wider range of antigens, with a resulting 40% improvement in RIC expression over the normal C-terminal fusion (C-RIC). Both types of RICs containing ZE3 were efficiently assembled in plants and purified to >95% homogeneity with a simple one-step purification. Both ZE3 RICs strongly bound complement receptor C1q and elicited strong ZE3-specific antibody titers that correlated with ZIKV neutralization. When either N-RIC or C-RIC was codelivered with plant-produced hepatitis B core (HBc) virus-like particles (VLP) displaying ZE3, the combination elicited 5-fold greater antibody titers (>1,000,000) and more strongly neutralized ZIKV than either RICs or VLPs alone, after only two doses without adjuvant. These findings demonstrate that antigens that require a free N-terminus for optimal antigen display can now be used with the RIC system, and that plant-made RICs and VLPs are highly effective vaccines targeting ZE3. Thus, the RIC platform can be more generally applied to a wider variety of antigens.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Diamos</LastName><ForeName>Andrew G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardhe</LastName><ForeName>Mary D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunter</LastName><ForeName>Joseph G L</ForeName><Initials>JGL</Initials><AffiliationInfo><Affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mor</LastName><ForeName>Tsafrir</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meador</LastName><ForeName>Lydia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilbourne</LastName><ForeName>Jacquelyn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Hugh S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, and The School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States. Electronic address: hugh.mason@asu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R33 AI101329</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Envelope protein</Keyword><Keyword MajorTopicYN="Y">Plant-made vaccine</Keyword><Keyword MajorTopicYN="Y">Recombinant immune complex</Keyword><Keyword MajorTopicYN="Y">Virus-like particle</Keyword><Keyword MajorTopicYN="Y">Zika virus</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Qiang Chen is an employee of GreenBio AZ and has no conflict of interest in publishing this manuscript. Hugh Mason is an unpaid advisor for FruitVaccine Inc. and has no conflict of interest in publishing this manuscript.].</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>09</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>02</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>02</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32173095</ArticleId><ArticleId IdType="pii">S0264-410X(20)30337-6</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2020.02.089</ArticleId><ArticleId IdType="pmc">PMC7102565</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Viral Immunol. 1998;11(4):245-52</Citation><ArticleIdList><ArticleId IdType="pubmed">10189191</ArticleId></ArticleIdList></Reference><Reference><Citation>Biotechnol J. 2012 Sep;7(9):1088-98</Citation><ArticleIdList><ArticleId IdType="pubmed">22890723</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein Expr Purif. 2018 Nov;151:86-92</Citation><ArticleIdList><ArticleId IdType="pubmed">29908914</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2014 Mar 14;343(6176):1260-3</Citation><ArticleIdList><ArticleId IdType="pubmed">24626930</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomed Res Int. 2014;2014:256135</Citation><ArticleIdList><ArticleId IdType="pubmed">24977145</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Plants. 2019 Jul;5(7):715-721</Citation><ArticleIdList><ArticleId IdType="pubmed">31285558</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2017 Jan 2;227:115-123</Citation><ArticleIdList><ArticleId IdType="pubmed">27751882</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Dec 11;28(2):352-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19879224</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2015 Apr 8;33(15):1830-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25728317</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Immunol. 2008 May;38(5):1404-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18389478</ArticleId></ArticleIdList></Reference><Reference><Citation>MAbs. 2017 Feb/Mar;9(2):182-212</Citation><ArticleIdList><ArticleId IdType="pubmed">28071970</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Rev. 2015 Nov;268(1):340-64</Citation><ArticleIdList><ArticleId IdType="pubmed">26497532</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2016 Dec;97(12):3280-3290</Citation><ArticleIdList><ArticleId IdType="pubmed">27902333</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant Biotechnol J. 2011 Sep;9(7):807-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21281425</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Mar 28;26(15):1846-54</Citation><ArticleIdList><ArticleId IdType="pubmed">18325641</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant Biotechnol J. 2018 Feb;16(2):572-580</Citation><ArticleIdList><ArticleId IdType="pubmed">28710796</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Negl Trop Dis. 2017 May 8;11(5):e0005608</Citation><ArticleIdList><ArticleId IdType="pubmed">28481898</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2017 Jul 24;35(33):4287-4294</Citation><ArticleIdList><ArticleId IdType="pubmed">28669618</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Antibodies. 2015 Dec 23;23(3-4):45-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27472861</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2019 Jan 3;37(1):137-144</Citation><ArticleIdList><ArticleId IdType="pubmed">30459071</ArticleId></ArticleIdList></Reference><Reference><Citation>F1000Res. 2016 May 19;5:</Citation><ArticleIdList><ArticleId IdType="pubmed">27274814</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2018 Dec 08;10(12):</Citation><ArticleIdList><ArticleId IdType="pubmed">30544785</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Apr 01;10(4):e0120751</Citation><ArticleIdList><ArticleId IdType="pubmed">25830365</ArticleId></ArticleIdList></Reference><Reference><Citation>J Microbiol Biotechnol. 2019 May 28;29(5):813-819</Citation><ArticleIdList><ArticleId IdType="pubmed">30982320</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2018 Jun 6;16(1):84</Citation><ArticleIdList><ArticleId IdType="pubmed">29871628</ArticleId></ArticleIdList></Reference><Reference><Citation>NPJ Vaccines. 2019 Jan 17;4:2</Citation><ArticleIdList><ArticleId IdType="pubmed">30675393</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2017 Nov 13;9(11):</Citation><ArticleIdList><ArticleId IdType="pubmed">29137162</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant Biotechnol J. 2004 May;2(3):241-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17147615</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2017 Jun 1;198(11):4235-4243</Citation><ArticleIdList><ArticleId IdType="pubmed">28432146</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2005 Apr 8;280(14):13406-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15684430</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Biol Ther. 2017 Oct;17(10):1185-1192</Citation><ArticleIdList><ArticleId IdType="pubmed">28644745</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2017 Oct 28;492(4):572-578</Citation><ArticleIdList><ArticleId IdType="pubmed">28630001</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein Expr Purif. 2011 Feb;75(2):218-24</Citation><ArticleIdList><ArticleId IdType="pubmed">20854910</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2013 Jan;9(1):26-49</Citation><ArticleIdList><ArticleId IdType="pubmed">22995837</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO Mol Med. 2016 Oct 4;8(10):1120-1133</Citation><ArticleIdList><ArticleId IdType="pubmed">27572622</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Plant Sci. 2019 Jan 09;9:1974</Citation><ArticleIdList><ArticleId IdType="pubmed">30687368</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 2005 Sep;73(9):5915-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16113311</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Bioeng Biotechnol. 2018 Jul 24;6:102</Citation><ArticleIdList><ArticleId IdType="pubmed">30087892</ArticleId></ArticleIdList></Reference><Reference><Citation>Biotechnol Bioeng. 2018 Mar;115(3):565-576</Citation><ArticleIdList><ArticleId IdType="pubmed">29178403</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2009 Nov;8(11):1565-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19863249</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant Biotechnol J. 2018 Dec;16(12):1971-1982</Citation><ArticleIdList><ArticleId IdType="pubmed">29637682</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2016 Apr 2;12(4):988-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26751099</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell. 2016 Jul 7;63(1):135-45</Citation><ArticleIdList><ArticleId IdType="pubmed">27320199</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1966 May;96(5):901-5</Citation><ArticleIdList><ArticleId IdType="pubmed">5913760</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Public Health. 2017 Mar - Apr;10(2):141-149</Citation><ArticleIdList><ArticleId IdType="pubmed">27283926</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2018 Jul 1;201(1):87-97</Citation><ArticleIdList><ArticleId IdType="pubmed">29752315</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2016 Aug 19;353(6301):823-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27417494</ArticleId></ArticleIdList></Reference><Reference><Citation>Glycobiology. 2019 Mar 1;29(3):199-210</Citation><ArticleIdList><ArticleId IdType="pubmed">30289453</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2016 May 11;19(5):696-704</Citation><ArticleIdList><ArticleId IdType="pubmed">27158114</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Trop Med Hyg. 2005 Feb;72(2):189-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15741556</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Oct 23;25(43):7559-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17869389</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20690-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22143789</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Plant Sci. 2016 Feb 24;7:200</Citation><ArticleIdList><ArticleId IdType="pubmed">26941764</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2017 Aug;16(8):781-787</Citation><ArticleIdList><ArticleId IdType="pubmed">28633549</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Arizona</li></region></list><tree><country name="États-Unis"><region name="Arizona"><name sortKey="Diamos, Andrew G" sort="Diamos, Andrew G" uniqKey="Diamos A" first="Andrew G" last="Diamos">Andrew G. Diamos</name></region><name sortKey="Chen, Qiang" sort="Chen, Qiang" uniqKey="Chen Q" first="Qiang" last="Chen">Qiang Chen</name><name sortKey="Hunter, Joseph G L" sort="Hunter, Joseph G L" uniqKey="Hunter J" first="Joseph G L" last="Hunter">Joseph G L. Hunter</name><name sortKey="Kilbourne, Jacquelyn" sort="Kilbourne, Jacquelyn" uniqKey="Kilbourne J" first="Jacquelyn" last="Kilbourne">Jacquelyn Kilbourne</name><name sortKey="Mason, Hugh S" sort="Mason, Hugh S" uniqKey="Mason H" first="Hugh S" last="Mason">Hugh S. Mason</name><name sortKey="Meador, Lydia" sort="Meador, Lydia" uniqKey="Meador L" first="Lydia" last="Meador">Lydia Meador</name><name sortKey="Mor, Tsafrir" sort="Mor, Tsafrir" uniqKey="Mor T" first="Tsafrir" last="Mor">Tsafrir Mor</name><name sortKey="Pardhe, Mary D" sort="Pardhe, Mary D" uniqKey="Pardhe M" first="Mary D" last="Pardhe">Mary D. Pardhe</name><name sortKey="Sun, Haiyan" sort="Sun, Haiyan" uniqKey="Sun H" first="Haiyan" last="Sun">Haiyan Sun</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PlantImRecepV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000194 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000194 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PlantImRecepV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32173095
|texte= Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32173095" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PlantImRecepV1
| This area was generated with Dilib version V0.6.38. |  |